Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and the Netherlands: insights from the ETNA-AF-Europe study.

peer reviewed ; BACKGROUND: Studies on the use of non-vitamin K antagonist oral anticoagulants in unselected patients with atrial fibrillation (AF) show that clinical characteristics and dosing practices differ per region, but lack data on edoxaban. METHODS: With data from Edoxaban Treatment in routiNe clinical prActice for patients with AF in Europe (ETNA-AF-Europe), a large prospective observational study, we compared clinical characteristics (including the dose reduction criteria for edoxaban: creatinine clearance 15-50 ml/min, weight ≤60 kg, and/or use of strong p‑glycoprotein inhibitors)... Mehr ...

Verfasser: de Vries, T A C
Hemels, M E W
Cools, F
Crijns, H J G M
Yperzeele, L
Vanacker, P
Blankoff, I
LANCELLOTTI, Patrizio
Mairesse, G H
de Veer, A
Casado Arroyo, R
Catez, E
de Pauw, M
Vanassche, T
de Asmundis, C
Kirchhof, P
De Caterina, R
de Groot, J R
ETNA-AF-Europe principal investigators from Belgium and the
Dokumenttyp: journal article
Erscheinungsdatum: 2021
Schlagwörter: Anticoagulants / Clinical trial / phase IV / Haemorrhage / Off-label use / Stroke / Thromboembolism / Human health sciences / Cardiovascular & respiratory systems / Sciences de la santé humaine / Systèmes cardiovasculaire & respiratoire
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26593152
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://orbi.uliege.be/handle/2268/291265